news
Dose-adjusted chemotherapy regimen effective in Burkitt lymphoma trial
Researchers reveal dose-adjusted (DA) EPOCH-R chemotherapy regimen was effective across all ages of Burkitt lymphoma patients in a Phase II clinical trial.
List view / Grid view
Anti-Cancer Therapeutics
news
FDA approves Lynparza (olaparib) for HRR mutated prostate cancer
Lynparza’s approval was based on results from a Phase III clinical trial in which it improved overall survival and progression-free survival in patients with certain prostate cancers.
news
FDA approves Tabrecta for treatment of metastatic non-small cell lung cancer
The FDA has approved Tabrecta (capmatinib) for patients with metastatic non-small cell lung cancer whose tumours have a mutation that leads to MET exon 14 skipping.
news
Attenuated diptheria toxin developed by researchers as novel form of drug delivery
A new potential platform for drug delivery has been created by researchers using attentuate diptheria toxin, which can enter cells and escape the endosome.
news
Novel antibody delivery method could improve precision medicine
Scientists have developed a protocol for encapsulating antibodies in an ultrasound-sensitive drug carrier for targeted drug delivery.
news
NICE recommends Vitrakvi (larotrectinib) for use on Cancer Drugs Fund
Larotrectinib has been given a positive opinion by NICE, following the submission of a revised price after it was previously rejected.
news
Novel cannabinoid formula could be used as a cancer treatment
The developers of the novel formulation, containing the cannabinoids CBDV and CBGA, now intend to test the clinical safety and efficacy of its anti-cancer activity.
news
75 percent of nanopharmaceuticals are being developed for oncology
A report states that three quarters of the roughly 230 nanopharmaceuticals in clinical development are for use as targeted cancer therapeutics.
news
Chinese ABRAXANE® supply expected to be disrupted
The marketing agent for China, BeiGene, announced the China National Medical Products Administration (NMPA) suspended the importation, sales and use of ABRAXANE.
news
Mass cytometry could reveal best cancer drug regimens for clinical trials
Researchers have developed a new technology that could provide real-time analysis of patient samples during clinical trials to reveal the best cancer treatment regimens.
news
NICE fails to recommend pembrolizumab in final draft guidance
The UK NICE has not found pembrolizumab cost-effective for use on the NHS, after a review of evidence collected while the drug was available via the Cancer Drugs Fund.
news
Flow cytometry market expected to reach $6.36 billion by 2027
New research suggests the flow cytometry sector will grow at a CAGR of 8.2 percent due to increased adoption and expanding uses.
news
STAR particles could be the future for treating skin conditions
Novel particles could be incorporated into topical creams to treat dermatological conditions without systemic exposure to drugs.
news
Gilead set to acquire Forty Seven for $4.9bn later in 2020
Gilead's acquisition of Forty Seven was unanimously approved by both companies' Boards of Directors, for $95.50 per share.
news
Innovations in CAR-T therapies in APAC will make market more competitive, report highlights
Research has shown that the CAR-T therapies in development in Asia-Pacific will make the worldwide market more competitive and drive down prices.
